Carsten Thiel, president of Europe for EUSA Pharma, recently led his company to launch several new medical products: Strensiq, Prolia, Vectbix, and Neulasta. Throughout the years he has been instrumental in spearheading medical innovations that have since drastically improved many thousands of lives.
He has done more than just help introduce and advance company products. He has also helped revolutionize the way the medical world as a whole behaves. Tiel was born and raised in Berlin, Germany. After graduating from high school, he studied Chemistry in Marburg.
Carsten Thiel then moved to the United Kingdom for further education at the University of Bristol. There he studied biochemistry. After obtaining a B.A. and Masters here, he did further study at the Max Planck Institute for Biophysical Chemistry, earning a Ph.D. In Molecular Biology. After obtaining all of this education, he got a position with the top biotechnology firm, Hoffman La-Roche. He started there as a Communications and Product Manager and quickly ascended to become head of scientific marketing. It was throughout the ensuing years that he utilized his own learning much and perfect new areas of biochemistry.
His biggest breakthrough up to that point was being instrumental in introducing a new weight loss product called Xenical. This marked the first time he had ventured into the world of marketing. This was the first time he had had to take seriously what the customer thought about the product. His input in this regard ended up being an enormous success and definitely paved the way for his future. Until this point, many weight loss drugs had failed because their companies made the mistake of marketing them with huge, unrealistic promises.
While these did result in big initial sales, these sales went way down because these customers were disappointed when the promised results did not materialize.
Carsten Thiel’s social Media: twitter.com/_carstenthiel